Disease · EFO_0020975

total knee arthroplasty

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. total knee arthroplasty. Diseases, record EFO_0020975. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0020975

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: total knee arthroplasty
Open Targets ID: EFO_0020975
Highest stage of its drugs: Phase 3, for 2 of its 11 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs11

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ROPIVACAINE	CHEMBL1077896	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
BUPIVACAINE	CHEMBL1098	Small molecule	Unknown	ClinicalTrials.gov	7	7	7	Drugs and targets
EPINEPHRINE	CHEMBL679	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
KETOROLAC	CHEMBL469	Small molecule	Unknown	ClinicalTrials.gov	2	2	2	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CLONIDINE	CHEMBL134	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MAGNESIUM SULFATE	CHEMBL3989857	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
MEPIVACAINE	CHEMBL1087	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 11

See all 11 drugs

Targets23

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor	3	Adrenergic receptor agonist; Adrenergic receptor alpha-2 agonist	Phase 3	https://conductscience.org/library/genes/152	Drugs and targets
SCN4A	Sodium channel alpha subunit	3	Sodium channel alpha subunit blocker; Sodium channel protein type IV alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6329	Drugs and targets
PTGS2	Cyclooxygenase	2	Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitor	Unknown	https://conductscience.org/library/genes/5743	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 2	https://conductscience.org/library/genes/6328	Drugs and targets

1 to 10 of 23

See all 23 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01042093	Efficacy of Multimodal Perioperative Analgesia With Periarticular Drug Injection in Total Knee Arthroplasty(TKA)	Not applicable	160	2013-11-08	Osteoarthritis,Knee	CLONIDINE, EPINEPHRINE, KETOROLAC, ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT02299349	Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection	Not applicable	70	2015-04-15	Total Knee Arthroplasty	BUPIVACAINE, EPINEPHRINE, KETOROLAC, MORPHINE, ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT07494032	Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty	Not applicable	350		Knee Arthropathy	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02286973	Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty	Phase 1	264		Degenerative Arthritis	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02393300	Comparison of Topical Versus Intravenous Tranexamic Acid in TKA	Phase 3	174		Total Blood Loss	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00537472	Low Dose Spinal Bupivacaine for Total Knee Replacement and Recovery Room Wait Time	Not applicable	140		Spinal Anesthesia, Total Knee Arthroplasty	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT06574269	A Study on TLC590 for Managing Postsurgical Pain	Phase 2	120		Postsurgical Pain Management	ROPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT06618820	Extended Oral Tranexamic Acid After Total Knee Arthroplasty	Phase 3	120		Osteo Arthritis Knee, Pain, Postoperative	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00474773	Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery		107		Pain Management, Function, Minimally Invasive Total Knee Arthroplasty, Celecoxib	CELECOXIB	Its record names the disease	ClinicalTrials.gov
NCT05438992	Different Bupivacaine Volumes in Infiltration Between Popliteal Artery and Capsule of Knee Block	Not applicable	105		Pain, Postoperative	BUPIVACAINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Bupivacaine Liposome Suspension vs Concentrated Multi Drug Injection: serious adverse events	0 of 35	0 of 35	70	NCT02299349

Source Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37060089	RESULT	1	PubMed
36856693	RESULT	1	PubMed
39653970	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0020975

GET https://conductscience.org/api/diseases/v1/EFO_0020975/targets?page=2

API reference For AI assistants